The global Molecular Cytogenetics Market, valued at US$0.97 billion in 2024, is projected to grow at a CAGR of 7.1%, reaching US$1.02 billion in 2025 and an impressive US$1.43 billion by 2030.
What’s Driving the Market?
- Rising incidence of cancer & genetic disorders
- Growing adoption of advanced cytogenetic technologies
- Increased use in clinical pathology testing
- Expanding opportunities in emerging markets
🔗 Download PDF Brochure
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224
Market Segmentation & Insights
🧪 By Product & Service
Kits & Reagents are expected to witness the fastest growth due to:
- High demand in research, diagnostics & clinical labs
- Streamlined workflows with ready-to-use kits
- Surge in specialized reagents and probes
- Strong innovation pipeline from leading manufacturers
🔬 By Technique
Comparative Genomic Hybridization (CGH) leads the market in 2024 and will continue dominating due to:
- High precision in detecting chromosomal abnormalities
- No need for cell culturing
- Rapid, reliable analysis of copy number variations (CNVs)
- Advanced array CGH boosting high-resolution detection—critical in oncology
🌏 By Region
Asia Pacific shows the fastest growth, driven by:
- Rising burden of cancer & genetic disorders
- Growing population
- Government investments in healthcare infrastructure
- Expanding presence of global and domestic players
🔗 Request Sample Pages
https://www.marketsandmarkets.com/requestsampleNew.asp?id=148469224
Key Players
Leading companies shaping the molecular cytogenetics landscape include:
Thermo Fisher Scientific, Illumina, Danaher, Roche, Revvity, Abbott, Agilent Technologies, PacBio, Bio-Rad, Bio-Techne.
Company Highlights
Agilent Technologies (US)
- Strong portfolio of instruments, reagents & software
- Focus on precision cytogenetic imaging & genomics
- 2025 updates: high-throughput solutions, workflow automation, R&D expansion
Abbott (US)
- Enhanced molecular cytogenetics presence through tech innovation
- Automated analyzers & assays supporting oncology and personalized medicine
- 2025 focus: integration of next-gen technologies through partnerships
